Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies

Key Inclusion Criteria:

1. Participants with Confirmed diagnosis of mature B-cell neoplasms including chronic lymphocytic leukemia/ small lymphocytic lymphoma, mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma and Waldenström's macroglobulinemia
2. Relapsed/refractory disease defined as disease that relapsed after, or been refractory to, at least 1 prior therapy
3. Meeting at least one of criteria for requiring treatment
4. Measurable disease by computed tomography (CT)/ magnetic resonance imaging (MRI) for mantle cell lymphoma (MCL), marginal zone lymphoma (MZL) and follicular lymphoma (FL) participants and by serum immunoglobulin (Ig) M level > 0.5 g/dL for WM participants
5. Eastern Cooperative Oncology Group performance status of 0, 1, or 2
6. Life expectancy of > 4 months

Key Exclusion Criteria:

1. Known central nervous system involvement by lymphoma/leukemia
2. Known plasma cell neoplasm, prolymphocytic leukemia, history of or currently suspected Richter's syndrome
3. Prior allogeneic stem cell transplant
4. Systemic chemotherapy or radiation therapy within 2 weeks prior to first dose of zanubrutinib
5. Active fungal, bacterial, and/or viral infection requiring systemic therapy
6. Prior therapy with B-cell receptor inhibitor (eg, Bruton tyrosine kinase, phosphoinositide 3 kinase delta, and/or spleen tyrosine kinase inhibitor) or B-cell lymphoma 2 inhibitor (eg, venetoclax/ABT-199)
7. Pregnant, lactating, or nursing women
8. Autoimmune anemia and/or thrombocytopenia that is poorly responsive to corticosteroids or other standard therapy

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.